These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy. Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637 [No Abstract] [Full Text] [Related]
6. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy". Baldovino S; Costanzo P; Roccatello D Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294 [No Abstract] [Full Text] [Related]
7. Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". Rozenbaum MH; Kemner J; Parasuraman B Circulation; 2020 Oct; 142(15):e210-e211. PubMed ID: 33044864 [No Abstract] [Full Text] [Related]
8. Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Dasgupta NR; Benson MD Amyloid; 2019; 26(sup1):20-21. PubMed ID: 31343363 [No Abstract] [Full Text] [Related]
9. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". Kazi DS; Bellows BK; Spertus JA; Baron SJ; Shen C; Cohen DJ; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ Circulation; 2020 Oct; 142(15):e212-e213. PubMed ID: 33044859 [No Abstract] [Full Text] [Related]
10. Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function. Martyn T; Saef J; Dey AR; Khedraki R; Jain V; Collier P; Jaber WA; Estep JD; Hanna M; Tang WHW JACC Heart Fail; 2022 Sep; 10(9):689-691. PubMed ID: 36049818 [No Abstract] [Full Text] [Related]
11. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg. Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332 [No Abstract] [Full Text] [Related]
12. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702 [No Abstract] [Full Text] [Related]
13. Reply: Racial and Genetic Differences: Possible Health Disparities in Transthyretin Amyloid Cardiomyopathy Patients? Martyn T; Saef J; Khedraki R; Hanna M; Tang WHW JACC Heart Fail; 2023 Jan; 11(1):130-131. PubMed ID: 36599541 [No Abstract] [Full Text] [Related]
14. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187 [TBL] [Abstract][Full Text] [Related]
15. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309 [TBL] [Abstract][Full Text] [Related]
16. Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTR Benson MD; Ackermann EJ; Monia BP Amyloid; 2017 Mar; 24(sup1):134-135. PubMed ID: 28434337 [No Abstract] [Full Text] [Related]
17. Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model. Teixeira C; Costelha S; Martins HS; Teixeira A; Saraiva MJ Amyloid; 2017 Mar; 24(sup1):80. PubMed ID: 28434372 [No Abstract] [Full Text] [Related]
18. Diagnosing transthyretin amyloidosis in patients with known genetic cardiomyopathies - opportunities and open questions. Casian M; Jurcut R Rev Esp Cardiol (Engl Ed); 2024 Jun; 77(6):504-505. PubMed ID: 38056771 [No Abstract] [Full Text] [Related]
19. Transthyretin Glu54Leu - an unknown mutation within the Swedish population associated with amyloid cardiomyopathy and a unique fibril type. Hellman U; Lång K; Ihse E; Jonasson J; Olsson M; Lundgren HE; Pilebro B; Westermark P; Wixner J; Anan I Scand J Clin Lab Invest; 2019 Oct; 79(6):372-376. PubMed ID: 31169435 [TBL] [Abstract][Full Text] [Related]
20. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Falk RH Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704 [No Abstract] [Full Text] [Related] [Next] [New Search]